Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Some Immuno-Oncology Drugs Carry Risk of Rare Heart Damage

XTALKS VITALS NEWS

Heart Damage

According to the authors, rare cases of fatal heart damage have occurred soon after patients started their course of immunotherapy treatment.

Share this!

November 7, 2016 | by Sarah Hand, M.Sc.

A new paper published in the New England Journal of Medicine has identified a previously-unknown side effect of certain immuno-oncology drugs. According to the authors, rare cases of fatal heart damage have occurred soon after patients started their course of immunotherapy treatment.

Two weeks after beginning treatment with Bristol-Myers Squibb’s Opdivo and Yervoy immuno-oncology drug combo, two melanoma patients died as a result of myocarditis. According to the authors, cancer patients being treated with this new class of drugs aren’t monitored for heart problems because this risk was previously unknown.

The drugs are both members of a promising new drug class in immuno-oncology, which some believe could have the potential to cause this side effect. “My sense is that this is a class effect, not limited to one drug,” said Dr. Javid Moslehi, a specialist in heart risks from cancer therapies.



Opdivo is a PD-1 checkpoint inhibitor, while Yervoy inhibits the CTLA-4 checkpoint. Many other drugmakers – including Merck & Co. and Roche – are developing drugs which target this PD-1/PD-L1 pathway.

Despite the recently-identified risk of heart damage associated with these immuno-oncology drugs, Moslehi says that doctors and patients should not discredit the drug class altogether. These therapies have been tremendously effective in some patient groups, so Moslehi says that those patients being treated with immunotherapy should be monitored for potential heart-related side effects.

“This is a new complication of potentially lifesaving drugs,” said Moslehi. “We’re working to develop treatments for it. Our job is not to say the drugs are bad, but to say, ‘How can we deal with it?’”

According to the article, the risk of myocarditis in patients taking the immuno-oncology drugs is small. Only 18 cases of serious heart-related side effects have been identified in the 20,594 patients who are receiving Opdivo and Yervoy as monotherapies, or in combination.


Keywords: Immuno-Oncology, Combination Therapy, Heart Damage


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.